Giordano Salvatore, Polimeni Alberto, Esposito Giovanni, Indolfi Ciro, Spaccarotella Carmen
Department of Medical and Surgical Sciences, Magna Græcia University of Catanzaro.
Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende.
Curr Opin Lipidol. 2023 Aug 1;34(4):133-140. doi: 10.1097/MOL.0000000000000877. Epub 2023 Mar 6.
To highlight critical aspects of inclisiran, from preclinical studies to current recommendations in clinical practice and future perspectives.
Inclisiran use has been recently approved by regulatory agencies. The evidence of its efficacy and safety makes it a promising therapeutical tool for treating dyslipidemias.
The link between LDL-cholesterol and atherosclerotic cardiovascular disease (ASCVD) is well established. Inclisiran, a small interfering RNA, has proven its safety and efficacy in reducing LDL-cholesterol, and FDA and EMA have recently approved its use. This review illustrates the development, structure, and mechanism of action of inclisiran and provides information regarding its efficacy, safety, and current recommendation in clinical practice. Moreover, it provides key information on the most recent/ongoing trials that will help us to implement the use of inclisiran in clinical practice.
强调inclisiran的关键方面，从临床前研究到临床实践中的当前建议以及未来展望。
inclisiran的使用最近已获得监管机构批准。其有效性和安全性的证据使其成为治疗血脂异常的有前景的治疗工具。
低密度脂蛋白胆固醇与动脉粥样硬化性心血管疾病（ASCVD）之间的联系已得到充分确立。inclisiran是一种小干扰RNA，已证明其在降低低密度脂蛋白胆固醇方面的安全性和有效性，并且美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）最近已批准其使用。本综述阐述了inclisiran的研发、结构和作用机制，并提供了有关其有效性、安全性以及临床实践中当前建议的信息。此外，它还提供了有关最新/正在进行的试验的关键信息，这将有助于我们在临床实践中应用inclisiran。
